Key clinical point: A prognostic score that incorporates copeptin levels, age, recanalization, and stroke risk score has been externally validated and accurately predicts unfavorable outcome, but not mortality, at 3 months.
Major finding: Diagnostic accuracy was 82% for the endpoint of unfavorable functional outcome at 3 months.
Study details: The prognostic score was developed based on a derivation cohort of 319 acute ischemic stroke patients and a validation cohort including another 783 patients in the Copeptin for Risk Stratification in Acute Stroke Patients (CoRisk) Study.
Disclosures: Study authors had nothing to disclose.
De Marchis GM et al. AAN 2019, Abstract S47.001